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Abstract
Medial degeneration is a key feature of aneurysm disease and aortic dissection. In a murine aneurysm model we
investigated the structural and functional characteristics of aortic wall degeneration in adult fibulin-4 deficient mice and the
potential therapeutic role of the angiotensin (Ang) II type 1 (AT1) receptor antagonist losartan in preventing aortic media
degeneration. Adult mice with 2-fold (heterozygous Fibulin-4+/R) and 4-fold (homozygous Fibulin-4R/R) reduced expression
of fibulin-4 displayed the histological features of cystic media degeneration as found in patients with aneurysm or
dissection, including elastin fiber fragmentation, loss of smooth muscle cells, and deposition of ground substance in the
extracellular matrix of the aortic media. The aortic contractile capacity, determined by isometric force measurements, was
diminished, and was associated with dysregulation of contractile genes as shown by aortic transcriptome analysis. These
structural and functional alterations were accompanied by upregulation of TGF-b signaling in aortas from fibulin-4 deficient
mice, as identified by genome-scaled network analysis as well as by immunohistochemical staining for phosphorylated
Smad2, an intracellular mediator of TGF-b. Tissue levels of Ang II, a regulator of TGF-b signaling, were increased. Prenatal
treatment with the AT1 receptor antagonist losartan, which blunts TGF-b signaling, prevented elastic fiber fragmentation in
the aortic media of newborn Fibulin-4R/R mice. Postnatal losartan treatment reduced haemodynamic stress and improved
lifespan of homozygous knockdown fibulin-4 animals, but did not affect aortic vessel wall structure. In conclusion, the AT1
receptor blocker losartan can prevent aortic media degeneration in a non-Marfan syndrome aneurysm mouse model. In
established aortic aneurysms, losartan does not affect aortic architecture, but does improve survival. These findings may
extend the potential therapeutic application of inhibitors of the renin-angiotensin system to the preventive treatment of
aneurysm disease.
Citation: Moltzer E, te Riet L, Swagemakers SMA, van Heijningen PM, Vermeij M, et al. (2011) Impaired Vascular Contractility and Aortic Wall Degeneration in
Fibulin-4 Deficient Mice: Effect of Angiotensin II Type 1 (AT1) Receptor Blockade. PLoS ONE 6(8): e23411. doi:10.1371/journal.pone.0023411
Editor: Pieter H. Reitsma, Leiden University Medical Center, Netherlands
Received December 9, 2010; Accepted July 16, 2011; Published August 9, 2011
Copyright:  2011 Moltzer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Netherlands Genomics Initiative (NGI)/NOW (to SS and PvdS) and by the ’Lijf en Leven’ grant (2008): ’Early Detection
and Diagnosis of Aneurysms and Heart Valve Abnormalities’ (to JE and PvH). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.essers@erasmusmc.nl
Introduction
Degeneration of the medial layer of the aorta is a key feature of
aneurysm disease and aortic dissection [1]. Cystic medial
degeneration is characterized by elastic fiber fragmentation, loss
of smooth muscle cells (SMC), and accumulation of amorphous
extracellular matrix (ECM) in the aortic wall. Although media
degeneration occurs to some degree with aging, excessive aortic
wall degeneration may lead to dilatation of the aorta and
aneurysm formation, or, alternatively, aortic dissection [2,3]. In
addition, advanced aortic degeneration may be part of inherited
disorders of the connective tissue. One of the most common of
these syndromes is Marfan syndrome (MFS), resulting from a
mutation in the FBN1 gene which encodes the ECM glycoprotein
fibrillin-1 [4]. MFS is characterized by elastic fiber fragmentation,
loss of elastin content, and accumulation of amorphous matrix
components in the aortic wall, resulting in the formation of
thoracic aortic aneurysms (TAAs) [5]. Mice with a mutation in the
fibrillin-1 gene are widely used to study the pathophysiologic
mechanisms underlying MFS and its treatment options [6].
Several mutations in other genes encoding extracellular matrix
proteins have also been identified in patients with TAAs, including
mutations in the fibulin-4 gene [7] [8]. Fibulin-4 is one of the
seven-member family of ECM proteins that play a role in elastic
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fiber assembly and function [9]. Fibulin-4 is highly expressed in
the medial layers of blood vessel walls, including the aortic media
[10]. It has been shown that mutant mice lacking fibulin-4
(Fibulin-4-/-) die perinatally from aortic rupture [11]. Further-
more, newborn mice with a systemic 4-fold reduced expression of
fibulin-4 (Fibulin-4R/R) display elastic fiber fragmentation and
develop aneurysms in the ascending thoracic aorta. Interestingly,
even a 2-fold reduced expression of fibulin-4 in the heterozygous
Fibulin-4+/R mice already induces similar, though milder, changes
in the aorta [12].
Since aneurysm disease is a condition of the aging population,
the present study first focused on the structural and functional
characterization of aortic wall degeneration in adult fibulin-4
deficient mice. Recent studies have shown that antagonizing
transforming growth factor-b (TGF-b) by either TGF-b neutral-
izing antibodies or the angiotensin (Ang) II type 1 (AT1) receptor
antagonist losartan can slow the progression rate of aortic root
dilatation in an MFS mouse model [6] and in patients with MFS
[13]. Therefore, we next investigated the role of the renin-
angiotensin system (RAS) in aneurysm formation in fibulin-4
deficient mice. We show that prenatal treatment with the AT1
receptor blocker losartan can prevent aortic media degeneration in
this non-MFS aneurysm mouse model. Losartan could not
attenuate established aortic aneurysms in adult fibulin-4 mice,
but largely improved survival of these animals. These findings
point towards potential therapeutic application of inhibitors of the
RAS to the preventive treatment of aneurysm disease.
Methods
Experimental animals
We previously generated a fibulin-4 allele with reduced
expression by transcriptional interference through placement of
a TKneo targeting construct in the downstream Mus81 gene [12].
Heterozygous (Fibulin-4+/R) mice in a mixed C57Bl/gJ;129Sv
background were mated to obtain Fibulin-4+/+, Fibulin-4+/R and
Fibullin-4R/R littermates and were housed in the institutional
animal facility. All experiments were performed under the
regulation and permission of the Animal Care Committee of the
Erasmus MC, Rotterdam, The Netherlands (protocol ID 139-08-
06). The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
Histology and immunohistochemistry
Mice (age 100 days) were euthanized by an overdose CO2, fixed
by perfusion fixation with 4% formaldehyde, and autopsied
according to standard protocols. Perfusion-fixed aortas were
isolated and paraffin embedded. Next, 4 mm sections were
haematoxylin and eosin stained and stained for elastin (Verhoeff-
van Gieson), glycosaminoglycans (Alcian Blue) and SMCs (a-
SMA). Immunohistochemistry for phosphorylated Smad2
(pSmad2) was performed as described previously [14] using rabbit
antiphospho-smad2 antibodies. The relative SMCs area of the
ascending aorta was quantified by calculating the surface area of
SMCs divided by the total surface area of the aortic rings (Qwin,
Leica, Gleisburg, Switzerland). The relative amount of positive
stained pSmad2 cells was calculated as the amount of positive
stained pSmad2 cells, divided by the total number of cells.
Hemodynamic measurements
Mice (15–20 weeks old) were sedated with 4% isoflurane and
intubated as previously described [15]. For measuring systolic and
diastolic BP, mice were instrumented with a calibrated high fidelity
1.4 Fr microtip pressure transducer catheter (SPR-671, Millar
Instruments), which was inserted into the left carotid artery and
advanced into the aortic arch [12]. Hemodynamic data were
recorded and digitized using an online 4-channel data acquisition
program (ATCODAS, Dataq Instruments, Akron, Ohio, USA),
for later analysis with a program written in Matlab. Ten
consecutive beats were selected for determination of BP.
Mulvany myographs
Male mice (age 120 days) were euthanized with an overdose of
pentobarbital i.p. (60 mg/kg). Thoracic aorta, abdominal aorta
and iliac artery were isolated and stored overnight in cold,
oxygenated Krebs-Henseleit buffer solution. The following day,
vessel segments were mounted in 6-mL organ baths (Danish
Myograph Technology, Aarhus, Denmark) containing Krebs-
Henseleit buffer (NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4) at 37uC and
oxygenated with 95% O2 and 5% CO2. The tension was
normalized to 90% of the estimated diameter at 100-mm Hg
effective transmural pressure.[16] Maximum contractile responses
were determined using 100 mmol/L KCl. Concentration response
curves (CRCs) were constructed to phenylephrine and Ang II
(Sigma); the latter with a 30-minute incubation with the NO
synthase inhibitor L-NAME (100 mmol/L; Sigma).
Microarray hybridizations
Standard procedures were used to obtain total RNA (Qiagen) of
two Fibulin-4+/+, two Fibulin-4+/R and four Fibulin-4R/R aortas
(10 days old). Synthesis and hybridization was performed as
described before [12]. To examine the quality of the various
arrays, several R packages (including affyQCreport) were run
starting from the CEL files. All created plots, including the
percentage of present calls, noise, background, and ratio of
GAPDH 39 to 59 (,1.4) indicated a high quality of all samples and
an overall comparability, except for two samples, which were
excluded from further analysis. Of the 45101 probe sets, ,55%
was called present in all samples. Raw intensities values of all
samples were normalized by robust multichip analysis normaliza-
tion (background correction and quantile normalization) using
Partek version 6.4 (Partek Inc., St. Louis, MO). The normalized
data file was transposed and imported into OmniViz version 6.0.1
(Biowisdom, Ltd., Cambridge, UK) for further analysis. For each
probe set, the geometric mean of the hybridization intensities of all
samples was calculated. The level of expression of each probe set
was determined relative to this geometric mean and 2log trans-
formed. The geometric mean of the hybridization signal of all
samples was used to ascribe equal weight to gene expression levels
with similar relative distances to the geometric mean. Differentially
expressed genes were identified using ANOVA (Partek) and SAM
(OmniViz). Cut-offs values for significantly expressed genes were
the FDR and a fold change of 1.5. Functional analysis was done
using IPA (Ingenuity, Mountain View, CA). Microarray experi-
ments have been previously described and complied with the
regulations for Minimum Information of Microarray Experiments
(MIAME) and can be retrieved from ArrayExpress (www.ebi.ac.uk/
arrayexpress/ , accession code: E-MEXP-840) [12].
Biochemical measurements
Kidneys were excised and blood was collected from the left
ventricle and stored in 4 mol/l guanine thiocyanate as described
before [17]. Both were immediately frozen in liquid nitrogen and
stored at280uC. Ang II was determined using radioimmunoassay,
following SepPak extraction and high-performance liquid chro-
matography separation [18].
Role of Renin-Angiotensin System in Fibulin-4 Mice
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23411
Quantitative real-time reverse transcription polymerase
chain reaction
Total RNA was isolated from kidneys and aortic arches using
RNeasy Fibrous Tissue Mini Kit (Qiagen) and reverse transcribed
using the SuperScript VILO cDNA synthesis kit (Invitrogen). The
resulting cDNA was amplified in 40 cycles (denaturation at 95uC
for 10 min; thermal cycling at 95uC for 15 sec, annealing/exten-
sion at 60uC for 1 min) with a Step-One cycler using TaqMan
Universal Mastermix and TaqMan probes (Applied Biosystems) of
individual genes. Specific primers (Rplp0 Mm01974474_gH,
Efemp2 Mm00445429_m1, Agtr1a Mm00616371_m1, Agtr1b
Mm02620758_s1 and Agtr2 Mm01341373_m1) were obtained
from Applied Biosystems. After PCR cycling, the fluorescence
intensities of the reporter (FAM) dyes were quantified. The
threshold cycle (Ct), i.e. the cycle number at which the amount of
the amplified gene of interest reached a fixed threshold, was
determined subsequently. The comparative Ct method (DDCT)
was used for relative quantification of gene expression [19].
Treatment
Fibulin-4+/R mice were bred to produce Fibulin-4+/+ and
Fibulin-4R/R mice. Pregnant mice received either propranolol
(0.5 g/liter, Sigma), losartan (0.6 gram/liter, Sigma) or placebo in
their drinking water as described before [6]. Treatment was
started at embryonic day (E)14.5 and continued for five days. At
E19.5 the pregnant mice were euthanized by an overdose CO2
and a caesarian section was performed to collect the fetuses. Adult
Fibulin-4R/R mice and their wild type littermates were treated
during 10–14.5 weeks, starting at the age of 5.5 weeks. Aortas from
the fetuses and adult mice were isolated and paraffin embedded.
Next, 4-mm sections were stained for elastin (Verhoeff-van Gieson).
Ascending aortic wall thickness is the average of four measure-
ments per quartile using Leica QWin software (Leica, Glattburg,
Switzerland).
Data-analysis
Normally distributed data are presented as mean6SEM. CRCs
were analyzed using Graph Pad Prism 5 (Graph Pad Software
Inc., San Diego, California, USA) to determine the maximum
effect (Emax) as described before.[20] Analysis of the differences
between CRCs was performed by two-way ANOVA. The one-
way ANOVA was considered for the analysis of Emax, blood
pressures, angiotensin II levels and vessel wall thickness. Both
analyses were followed by post hoc evaluation according to
Bonferroni. To compare the observed distributions of the geno-
types with the expected mendelian distribution, a chi-square test
was used. The survival of fibulin-4 mice over time is presented in a
Kaplan-Meier curve for a cohort of mice alive at age 3 weeks and
the curves were compared by the Log Rank test. To evaluate the
dose-dependent effect of fibulin-4 expression, a linear regression
analysis was performed to obtain a p for trend. The latter statistical
analyses were performed using SPSS 15.0 for Windows (SPSS,
Chicago, Ill, USA). All statistical tests were two-sided and a
p-value ,0.05 was considered statistically significant.
Results
Adult fibulin-4 deficient mice display aortic wall
degeneration
Newborn Fibulin-4R/R mice already showed severe TAAs [12],
but only a small number of Fibulin-4R/R mice survived towards
adult age. Fig. 1 shows the survival of fibulin-4 deficient mice.
Newborn fibulin-4 mice demonstrate a Mendelian distribution of
the three genotypes (30.2% Fibulin-4+/+, 46.5% Fibulin-4+/R and
23.3% Fibulin-4R/R mice). Due to the high mortality in the first
weeks, genotyping takes place at the age of three weeks. At this
age, the amount of Fibulin-4R/R mice already dropped to 15%
and the Mendelian distribution is lost (Fig. 1A, p,0.0001). To get
insight in the mortality rate of these mice, we constructed a
Kaplan-Meier curve with all mice alive at the age of three weeks
(Fig. 1B). The curves clearly demonstrate a dramatic survival of
Fibulin-4R/R mice when compared to their wild type littermates
(p,0.0001). The structural alterations resulting from reduced
fibulin-4 in adult mice were characterized in 100-days-old mice.
All aneurysms of Fibulin-4R/R mice were located in the ascending
thoracic aorta. Aortic wall thickness was increased in Fibulin-4+/R
and Fibulin-4R/R as compared with Fibulin-4+/+ mice (Fig. 2A–C).
The increase in aortic wall thickness was, at least in part, due to
increased deposition of glycosaminoglycans in the ECM, as
demonstrated by Alcian blue staining (Fig. 2D–F). Aortas of wild
type mice displayed a normal pattern of elastic lamellae forming
dense parallel sheets. In contrast, the thickened aortic walls in
fibulin-4 deficient mice displayed changes in elastic fiber
organization, varying from moderate elastic fiber fragmentation
in Fibulin-4+/R mice to complete destruction of elastin lamellar
organization in Fibulin-4R/R mice (Fig. 2G–I). In addition to
changes in elastin structure, aortic walls of Fibulin-4+/R and
Fibulin-4R/R mice displayed loss of SMCs, as evidenced by a-
smooth muscle actin (SMA) staining (Fig. 2J–L) and increased
numbers of apoptotic cells (data not shown). Next, to evaluate
the reduction of SMCs seen in Fibulin-4R/R aortas, we quantified
the amount of SMCs relative to the vessel wall area. Although
the absolute amount of SMCs varied among the different
genotypes, the relative amount of SMCs was significantly lower
in Fibulin-4R/R mice when compared to Fibulin-4+/+ and
Fibulin-4+/R mice (Fig. 2M).
Functional consequences of fibulin-4 deficiency
Increased aortic pulse pressure. Since elastic fiber
fragmentation may be associated with loss of elasticity and
increased stiffness of the aortic wall, we next determined the in vivo
aortic blood pressure using a microtip pressure catheter. In Fibulin-
4R/R mice a slightly increased systolic blood pressure and decreased
diastolic blood pressure was observed compared to wild type animals
resulting in a significantly higher aortic pulse pressure in Fibulin-4R/R
mice compared to controls (Fig. 3), which is consistent with increased
arterial stiffness [21]. Interestingly, we observed a gene dose-
dependent decrease (trend) in diastolic blood pressure and increase
(trend) in pulse pressure (Fig. 3), while no aortic valve abnormalities
are present in Fibulin-4+/R mice. We therefore hypothesize that this
blood pressure effect is due to primary vessel wall impairment in
fibulin-4 deficient mice, while in Fibulin-4R/R mice, this phenotype is
aggravated due to aortic valve dysfunction.
Reduced aortic contractility. To evaluate the functional
effects of SMC loss, in vitro vascular contractility was studied in
different segments of the aorta and the iliac arteries. After
mounting, the vessel diameter was measured for each segment.
Ascending thoracic aortic diameters were 1106622, 1086627 and
2023688 mm for Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R
mice respectively (n = 14–18). Descending thoracic aortic dia-
meters were 830617, 797617 and 955649 mm for Fibulin-4+/+,
Fibulin-4+/R and Fibulin-4R/R mice respectively (n = 17–22).
Abdominal aortic diameters were 568612, 585615 and
611630 mm for Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R
mice respectively (n = 18–20). Iliac arteries were 420612,
401611 and 378614 mm for Fibulin-4+/+, Fibulin-4+/R and
Fibulin-4R/R mice respectively (n = 18–19). The diameter of both
Role of Renin-Angiotensin System in Fibulin-4 Mice
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the ascending and descending thoracic aorta were significantly larger
in Fibulin-4R/R mice when compared to wild type Fibulin-4+/+mice,
while the iliac arteries were significantly smaller in diameter.
Furthermore, the increase in vessel diameter of the ascending
thoracic aorta was accompanied by an approximately 2-fold elonga-
tion of the aortic segment.
In line with the relative reduction of SMCs in the thoracic aorta,
the maximum contractility of thoracic aortas in response to KCl
(100 mmol/L) was more than 3-fold lower in Fibulin-4R/R mice
than in Fibulin-4+/+ mice (Fig. 4A). Similarly, receptor-mediated
vasoconstriction in response to phenylephrine (100 mmol/L) was
significantly lower in thoracic aortic rings of Fibulin-4R/R mice
than in Fibulin-4+/+ mice (Fig. 4B). The contractile responses of
the abdominal aorta and the iliac arteries did not differ between
groups (data not shown). Increasing doses of Ang II, following a
30-minute incubation with Nv-nitro-L-arginine methyl ester (L-
NAME), did not induce vasoconstriction in the thoracic aorta
(Fig. 3C–D). The contractile responses of the abdominal aorta and
iliac arteries in response to Ang II were not different between
fibulin-4 deficient and wild type mice (Fig. 4E–F). This difference
probably relates to the lower AT1 receptor levels in the thoracic
aorta than in other large arteries in the mouse [22,23].
Disturbed calcium signaling in fibulin-4 deficient mice
Next, genome-scaled network analysis from Fibulin-4+/+,
Fibulin-4+/R and Fibulin-4R/R aortas was performed using
dedicated microarray statistics with a focus on canonical pathway
analysis. Differentially expressed genes were initially identified
using statistical analysis of microarrays ANOVA (false discovery
rate (FDR) 0.5 and 1.5-fold change up- or downregulation).
Transcriptomes of Fibulin-4+/+ and Fibulin-4+/R full length
aortas were compared and 26 probe sets were identified. With
Ingenuity Pathway Analysis (IPA), a list of involved canonical
pathways was constructed (Supplemental Table S1). The calcium
signaling showed up as the top canonical pathway. Next, an
independent SAM analysis was performed (FDR of 0.0032 (falsely
called ,1) and 1.5-fold change up- or downregulation). This
approach identified 279 probe sets, from which a second top list of
canonical pathways was constructed (Supplemental Table S2).
Again, the calcium signaling pathway was highly significant.
Interestingly, very specific genes involved in muscle cell contrac-
tion were up- or downregulated (Fig. 5).
Next, differences between transcriptomes of Fibulin-4+/+ and
Fibulin-4R/R aortas were analyzed. Statistical analysis of micro-
arrays ANOVA was performed with the same selection criteria as
for Fibulin-4+/+ vs. Fibulin-4+/R aortas. Canonical pathway analysis
identified mainly pathways involved in immunological and
inflammatory diseases (Supplemental Table S3) and after analysis
with SAM (FDR 0.2 and 1.5-fold change up- or downregulation) a
table with principally similar pathways was constructed (Supple-
mental Table S4). These analyses identified a few genes involved in
the aforementioned calcium signaling pathway.
Figure 1. Survival of fibulin-4 mice. (A) Distribution of the three genotypes at 0 and 3 weeks of age. The grey bars show the expected Mendelian
distribution and the overlying bars the observed distribution of the different genotypes. Fibulin-4 mice are born in a Mendelian distribution (n = 10–
20). Already after three weeks, this distribution is lost (n = 50–180, p,0.0001). (B) Kaplan-Meier survival curves of Fibulin-4+/+, Fibulin-4+/R and Fibulin-
4R/R mice alive at the age of three weeks (n = 50–180). After 21 weeks, 96% of wild type Fibulin-4+/+ and 92% of Fibulin-4+/R mice survived. Survival of
Fibulin-4R/R mice dramatically decreased to 33% (p,0.0001 vs. wild type). Note that the survival curve starts with all mice alive at the age of three
weeks. Symbols indicate censored data.
doi:10.1371/journal.pone.0023411.g001
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Fibulin-4 deficient mice show dysregulation of TGF-b
signaling and increased tissue angiotensin II
In a mouse model of MFS, it has been demonstrated that
dysregulation of TGF-b activation and the RAS play an important
role in aneurysm formation [6,24,25]. Hence, we next investigated
the involvement of TGF-b signaling and Ang II in fibulin-4
deficient mice. First, genome-scaled network analysis from Fibulin-
4+/+, Fibulin-4+/R and Fibulin-4R/R aortas identified the upregu-
lation of TGF-b in Fibulin-4R/R mice compared to Fibulin-4+/+
mice (Supplemental Table S3 and S4). Next, immunohistochem-
ical staining for phosphorylated Smad2 (pSmad2), an intracellular
mediator of the TGF-b signal, in ascending thoracic aortas was
performed. A graded increase in the nuclear translocation of
pSmad2 in the aortic media of Fibulin-4+/R and Fibulin-4R/R
mice was observed (Fig. 6A), indicating increased TGF-b signaling
in adult aneurysmal fibulin-4 deficient mice.
Ang II is important in TGF-b signaling, by stimulating TGF-b1
mRNA and protein expression, which leads to TGF-b activation.
This indicates that TGF-b acts downstream of Ang II signaling
[26]. Therefore, we subsequently measured Ang II levels in blood
and in kidney tissue of fibulin-4 deficient mice. Plasma Ang II
levels were identical in the three genotypes (Fig. 6B). In contrast,
renal tissue Ang II levels displayed a clear gene dose-dependent
increase in Fibulin-4+/R and Fibulin-4R/R mice (Fig. 5b; p,0.004
for gene deletion effect), which may be due to increased AT1
receptor binding at this site, resulting in increased receptor-
Figure 2. Architecture of ascending thoracic aortas. In adult Fibulin-4+/R and Fibulin-4R/R aortas there is an increase in aortic wall thickness (A–
C), glycosaminoglycan depositions (blue areas) (D–F), elastic fiber fragmentation (G–I) and loss of smooth muscle cells in the media (J–L), also
quantified (M).
doi:10.1371/journal.pone.0023411.g002
Role of Renin-Angiotensin System in Fibulin-4 Mice
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23411
bounded Ang II levels [27]. Subsequent analysis of angiotensin
receptor expression indeed demonstrated increased AT1b receptor
expression in both the kidneys and aortic arches (Fig. 6C). It is thus
reasonable to assume that the Ang II content is also larger in the
vasculature of fibulin-4 deficient mice, due to an increased
receptor density at this site.
Treatment with AT1 receptor blocker losartan prevents
aortic wall degeneration, but does not attenuate
established aortic aneurysms
In genetically engineered MFS mice with abnormal fibrillin-1,
blocking TGF-b, either by TGF-b neutralizing antibody or by the
AT1 receptor blocker losartan, has been shown to prevent aortic
root dilatation, elastic fiber degeneration, and pSmad2 activation
[6]. Since dysregulation of TGF-b signaling and activation of the
RAS were also observed in fibulin-4 deficient mice, we next
investigated the potential therapeutic effect of losartan. To prevent
Fibulin-4R/R mice for premature drop-out due to aortic rupture,
mice were treated as early as possible. Thus, mice were prenatally
treated with placebo, beta-adrenergic receptor blocker propran-
olol, or AT1 receptor blocker losartan. Propranolol, used as
standard therapy to slow progression rate of aortic root growth in
patients with MFS, served as control agent in an equihypotensive
dosage [6]. Cross-sections of ascending aortas collected from
Fibulin-4+/+ newborn mice, revealed the presence of intact elastic
layers (Fig 7A). As expected, placebo-treated Fibulin-4R/R mice
showed severe fragmentation and an increased aortic wall
thickness in this area (Fig. 7A–B). Treatment of Fibulin-4R/R
mice with propranolol did not change elastic fiber fragmentation,
but slightly lowered vessel wall thickness. Yet, treatment with
losartan improved elastic fiber fragmentation and greatly reduced
vessel wall thickness.
Since AT1 receptor blockade is contraindicated during
pregnancy and aortic aneurysms are usually diagnosed in a more
advanced state, we performed a postnatal treatment trial with
losartan. While only a minority of the Fibulin4R/R untreated mice
reach a lifespan of 120–140 days, losartan-treated Fibulin4R/R
animals could reach a lifespan of at least 160–180 days (n = 3),
after which they were sacrificed for histological analysis. Postnatal
treatment of Fibulin-4R/R mice with losartan did not reduce vessel
wall thickness, but contrary, led to aortic wall thickening when
compared to placebo-treated Fibulin-4R/R mice (Fig. 7D). This
might, at least in part, be due to the increase in age of the losartan-
treated animals. There were no signs of active remodeling of the
aortic wall due to losartan treatment, since no change in elastic
fiber architecture (Fig. 7C) or lumen diameter (Fig. 7F) was
observed. To address whether losartan was able to reduce TGF-b
signaling in these adult animals we performed pSmad2 staining.
We found no reduction in pSmad2 positive cells with 99% of all
nuclei stained positive for both groups (Fig. 7E). Since losartan
reduced systolic blood pressure to approximately 60 mmHg, we
therefore attribute the increased lifespan of the losartan-treated
animals to the lower blood pressure measured.
Discussion
Adult fibulin-4 deficient (Fibulin-4+/R and Fibulin-4R/R) mice
display gene-dose-dependent elastic fiber fragmentation, dropout
of SMCs, and deposition of mucopolysaccharide ground substance
in the ECM of the aortic media. The structural changes observed
in adult fibulin-4 deficient mice reflect the key histological features
of cystic medial degeneration in patients with aortic aneurysm or
dissection [1,28,29]. In patients, medial degeneration is histolog-
ically characterized by fragmentation and loss of elastin, loss of
SMCs, and formation of areas devoid of elastin that are filled with
amorphous ECM. Cystic medial degeneration characterizes the
final common pathway for various processes that affect the
integrity of the aortic media. These findings support the use of the
fibulin-4 deficient murine model for the study of aortic
degeneration and aneurysm formation and its pharmacothera-
peutical intervention.
The ECM provides the structural and functional platform of the
aorta. In normal healthy aorta, elastin and collagen account for
50% of the dry weight and provide the aortic wall with non-linear
elasticity properties [30]. One of the critical elements of the ECM
are the elastic lamellae. Elastin is incorporated in elastic fibers on a
scaffold of microfibrils. The elastic fibers in normal healthy aorta
are arranged in concentric elastic lamellae and, together with
vascular SMCs, form lamellar units [31]. Deposition of elastin is
not uniform in the aorta, with a decrease in the number of elastin
lamellar units from the ascending aorta to the abdominal aorta
[30]. The circumferentially aligned collagen and elastin fibers in
the aortic media provide tensile strength, permitting the aorta to
withstand pulsatile flow and blood pressure delivered by the heart
and to limit distal shear stress. The loss of elastic fiber integrity in
the aortic wall observed in fibulin-4 deficient mice was associated
with an increase in aortic pulse pressure, mainly due to a decline in
diastolic blood pressure, reflecting diminished aortic resilience and
tensile strength. Similar stiffening of the aortic wall with increased
pulse pressure has been found in the well-characterized genetically
engineered mouse model of MFS with a mutation in the FBN1
gene (Fbn1C1039G/+) and in patients with MFS [32] [33]. The rise
in aortic pulse pressure in conjunction with aortic dilatation will
further increase arterial wall stress over the cardiac cycle and
thereby extend elastic fiber fragmentation. In MFS patients it has
been shown that elevated aortic pulse-wave velocity, as a measure
for reduced aortic elasticity, is a predictor for aortic dilatation and
dissection [34].
The changes in aortic media structure were accompanied by
impaired contractile function. Both adrenergic-receptor and
receptor-independent vascular contractility were reduced in
fibulin-4 deficient aortic rings. The decreased contractile capacity
could, at least in part, be explained by the loss of SMCs in fibulin-4
deficient aortas. In addition, loss of fibulin-4 is assumed to disrupt
Figure 3. Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) measured using an intra-aortic microtip
pressure transducer catheter. With decreasing expression of
Fibulin-4, DBP decreased and pulse pressure (PP) increased (p for trend
0.009 and,0.001 resp.). Data are mean6SEM of 4–17 mice. *p,0.05 vs.
Fibulin-4+/+ and Fibulin-4+/R (two-way ANOVA).
doi:10.1371/journal.pone.0023411.g003
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the interaction between elastic fibers and SMCs, leading to
alterations in actin cytoskeleton organization [35]. Third, altered
calcium signaling may contribute to disturbed vascular contractile
capacity. Using aortic transcriptome analysis, we identified altered
expression pattern of genes encoding for proteins involved in
calcium signaling in Fibulin-4+/R as compared with Fibulin-4+/+
aortas. These data indicate that fibulin-4 deletion not only affects
aortic media structure, but also affects contractile function, as was
also predicted based on fibulin-4 conditional knockout mice [35].
It has been suggested that aortic contractility contributes to the
overall tensile strength and structural integrity of the aortic wall
[36]. The observed disturbances in the biomechanical properties
of the aorta are in line with findings in the genetic mouse model of
MFS [37]. The altered load-bearing capacity of the aorta due to
disturbances in the synthesis and breakdown of the aortic medial
ECM as well as impaired aortic contractility culminates in
increased aortic wall stress, which may contribute to dissection
and aneurysm formation.
As in the MFS mouse model, the alterations in aortic structure
and function were associated with increased TGF-b signaling in
adult aneurysmal fibulin-4 deficient mice, as evidenced by a
graded increase in the expression of pSmad2, an intracellular
mediator of the TGF-b signal, in the aortic media of Fibulin-4+/R
and Fibulin-4R/R mice. Augmented TGF-b activation is associated
with upregulation of matrix metalloproteinases and degradation of
the aortic media, as shown in both MFS mice and in newborn
fibulin-4 deficient mice [37,38,39]. Furthermore, altered TGF-b
signaling has also been reported in humans with cardiovascular
malformations due to fibulin-4 deficiency [40]. The importance of
TGF-b signaling in aneurysm formation is further supported by
the recent demonstration of increased circulating TGF-b concen-
trations in patients and mice with MFS, and the correlation
between increased serum TGF-b and aortic root dilatation [41].
It is still unclear how fibulin-4 deficiency correlates with
increased TGF-b signaling. Increased TGF-b production may be
due to Ang II [42,43,44,45]. For example, in human vascular
SMCs, stimulation with Ang II induced a 6-fold increase in TGF-b
production [43]. The contribution of the RAS in the fibulin-4
mouse model was investigated by measuring circulating and renal
tissue Ang II. Changes in renal Ang II content mirror changes in
Figure 4. Contractility mediated by KCl, phenylephrine and angiotensin II. (A) In ascending aortas, KCl-induced contractility decreased in a
gene dose-dependently in Fibulin-4+/R and Fibulin-4R/R mice (p for trend ,0.001). (B) In descending aortas, phenylephrine-induced contractility
decreased gene dose-dependently in Fibulin-4+/R and Fibulin-4R/R mice (p for trend 0.004). Data are mean6SEM of 6–18 experiments, *p,0.05 vs.
Fibulin-4+/+ mice. (C–F) Effect of angiotensin II on (C) ascending thoracic aortas, (D) descending thoracic aortas, (E) abdominal aortas and (F) iliac
arteries. Data (mean6SEM of 3–6 experiments) are shown as a percentage of the response to 100 mmol/L KCl.
doi:10.1371/journal.pone.0023411.g004
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the Ang II content of other tissues, including the aorta [17,27].
However, renal Ang II levels are generally much higher than Ang
II levels in blood vessel walls, and can thus be measured with much
greater accuracy. Therefore, we determined renal tissue Ang II
levels as a reflection of changes in aortic Ang II content in adult
fibulin-4 deficient mice. While Ang II levels were preserved in
plasma, renal Ang II levels increased with decreasing expression of
fibulin-4. Parallel increases in renal AT1b receptor content were
observed, although these increases were not yet significant at
n = 3–10. Since tissue Ang II levels are determined largely, if not
completely, by AT1a and/or AT1b receptor binding and
subsequent internalization of extracellularly generated Ang II
[17,27], these data suggest that the increased renal Ang II levels
are due to increased renal AT1 receptor binding. Importantly,
qPCR supported an aortic AT receptor upregulation profile in
these mice that was identical to the profile in the kidney, i.e.,
selective AT1b upregulation. Thus, based on these data it seems
reasonable to assume that the vascular Ang II levels, like the renal
Ang II levels, are increased in fibulin-4 deficient mice due to
increased AT1 receptor binding. Alternatively, upregulated tissue
Figure 5. Calcium signaling pathway in a resting muscle cell (Fibulin-4+/R vs. Fibulin-4+/+ aortas). Colors show up- (red) and
downregulation (green) of molecules involved in muscle cell contraction.
doi:10.1371/journal.pone.0023411.g005
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Ang II levels may be due to increased renin uptake at tissue sites
[46], and thus future studies should investigate vascular (pro)renin
receptor density. Evidence is accumulating that the RAS plays an
important role in the pathogenesis of aneurysm formation
[6,25,47,48,49]. Ang II and AT2 receptor expression are increased
in MFS aortic tissue and have been associated with cystic medial
degeneration [25]. The increased tissue Ang II levels observed in
fibulin-4 deficient mice are in line with these findings and support
the role for the RAS in this model.
Drugs that interfere with the RAS may reduce aortic media
degeneration. In cultured aortic cells from MFS, angiotensin-
converting enzyme inhibition and AT1 receptor antagonism
significantly inhibited SMC apoptosis [25]. Interestingly, blockade
of the AT1 receptor by losartan has been shown to diminish TGF-
b signaling, with a reduction in free TGF-b levels, tissue expression
of TGF-b–responsive genes, and levels of mediators within the
TGF-b signaling cascade, and to prevent aortic aneurysm
development in the MFS mouse model [6]. Furthermore,
treatment with losartan reduced circulating TGF-b levels and
slowed the rate of aortic root dilatation both in MFS mice and in
MFS patients [13,41]. Based on these findings, we investigated
whether aortic media degeneration in the fibulin-4 aneurysm
model is associated with increased TGF-b signaling and could be
prevented by the TGF-b antagonist losartan. In addition to
interfering with TGF-b signaling, AT1 receptor blockade will
indirectly stimulate the AT2 receptor. Through a negative
Figure 6. Increased levels of pSmad2 and angiotensin II in fibulin-4 mutant aortas. (A) Immunhistochemistry reveals a graded increase in
expression and nuclear translocation of pSmad2 in the aortic media of adult fibulin-4 deficient mice. (B) With reduced fibulin-4 expression, tissue (but
not blood) Ang II levels increase (p for trend 0.004). Data are shown as mean6SEM of 4–18 experiments. *p,0.05 vs. Fibulin-4+/+. (C) Relative mRNA
expression of Fibulin-4 and Ang II receptors. As published previously, a substantial decrease of fibulin-4 was observed in Fibulin-4+/R and Fibulin-4R/R
mice when compared to wild type littermates. Both the renal and aortic arch AT1b receptor content was larger in Fibulin-4
R/R mice when compared to
Fibulin-4+/+ and Fibulin-4+/R mice. No differences in AT1a or AT2 receptor expression were observed between the different genotypes (n = 3–10).
AT1aR, angiotensin II type 1a receptor; AT1bR, angiotensin II type 1b receptor; AT2R, angiotensin II type 2 receptor.
doi:10.1371/journal.pone.0023411.g006
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Figure 7. Aortic aneurysm treatment with losartan. (A) Elastic fiber fragmentation in newborn Fibulin-4R/R mice could be prevented with
losartan, but not with propranolol or placebo. (B) Vessel wall thickness of thoracic aortas from newborn Fibulin-4+/+ and treated Fibulin-4R/R mice.
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feedback-mechanism, Ang II levels rise and bind the AT2 receptor,
which can have positive effects on the vascular remodeling. Results
obtained in MFS mice further demonstrate that losartan is able to
improve phenylephrine-induced contractility [50].
AT1 receptor blocker losartan, but not by the b-blocker
propranolol, prevented elastic fiber fragmentation and disarray
in the aortic media of newborn Fibulin-4R/R mice. Treatment of
established aortic aneurysms in adult fibulin-4 mice with these
losartan doses (0.6 g/L) did not affect elastic fiber architecture.
Thus, losartan was only able to prevent aortic wall degeneration in
newborn Fibulin-4R/R mice. This is opposite to findings in MFS
mice, where postnatal treatment did improve aortic wall
degeneration [6]. Clearly, there are differences between the
mouse models. All Fibulin-4R/R mice suffer from severe aortic
aneurysms from birth that are prone to rupture, resulting in a
tremendous reduction in lifespan as compared to their wild type
littermates. MFS mice start to develop aortic aneurysms at the age
of two months with variable severity of the aneurysm, and have a
normal lifespan [51]. We hypothesize that aortic damage of
Fibulin-4R/R mice at the age of 5.5 weeks is too severe to regress or
prevent further aortic growth with losartan treatment. Therefore,
no difference in vessel lumen could be observed between placebo-
or losartan-treated Fibulin-4R/R mice. Most importantly, lifespan
of adult Fibulin-4R/R mice treated with losartan largely improved,
accompanied with an increase with vessel wall thickness. Thus,
thickening of the aortic wall might prevent aortic rupture.
Postnatal losartan treatment of Fibulin-4R/R animals neither
resulted in improved vessel wall structure nor in reduced TGF-b
signaling, arguing against an active remodeling of the aorta.. Thus,
the improved lifespan seem to be a result of a reduced
haemodynamic stress, evidenced by a lower blood pressure.
Whether results are specific for AT1 receptor blockers and/or
inhibitors of the renin-angiotensin system or whether similar
effects can be obtained with other blood pressure lowering agents
has to be evaluated.
The present study is the first to show that losartan is effective in
the prevention of non-MFS based aortic aneurysms. For established
aortic aneurysms, losartan proved to largely improve lifespan,
accompanied with a (preventive) thickening of the aortic wall.
Together with previous reports, these data suggest that the
antihypertensive drug losartan, an AT1 receptor blocker that blunts
TGF-b activation, may be an effective drug in the early secondary
prevention of aortic media degeneration and aneurysm formation.
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